BridgeBio Pharma (Germany) Today
| 2CL Stock | EUR 65.52 1.58 2.47% |
PerformanceGood
| Odds Of DistressLow
|
BridgeBio Pharma is trading at 65.52 as of the 2nd of February 2026. This is a 2.47% up since the beginning of the trading day. The stock's lowest day price was 65.16. BridgeBio Pharma has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 4th of November 2025 and ending today, the 2nd of February 2026. Click here to learn more.
Category Healthcare |
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. BRIDGEBIO PHARMA operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. The company has 191.63 M outstanding shares. More on BridgeBio Pharma
Moving together with BridgeBio Stock
Moving against BridgeBio Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BridgeBio Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BridgeBio Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BridgeBio Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Neil Kumar |
| Business Concentration | Biotechnology, Healthcare, Biotechnology, Healthcare (View all Sectors) |
BridgeBio Pharma (2CL) is traded on Frankfurt Exchange in Germany and employs 725 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 12.79 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BridgeBio Pharma's market, we take the total number of its shares issued and multiply it by BridgeBio Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BridgeBio Pharma classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 191.63 M outstanding shares.
BridgeBio Pharma has accumulated about 837.66 M in cash with (470.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59.
Check BridgeBio Pharma Probability Of Bankruptcy
Ownership AllocationBridgeBio Pharma retains a total of 191.63 Million outstanding shares. The majority of BridgeBio Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BridgeBio Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BridgeBio Pharma. Please pay attention to any change in the institutional holdings of BridgeBio Pharma as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check BridgeBio Ownership Details
BridgeBio Pharma Risk Profiles
Although BridgeBio Pharma's alpha and beta are two of the key measurements used to evaluate BridgeBio Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.94 | |||
| Semi Deviation | 1.89 | |||
| Standard Deviation | 2.83 | |||
| Variance | 7.99 |
BridgeBio Stock Against Markets
BridgeBio Stock Analysis Notes
About 95.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 3.52. BridgeBio Pharma had not issued any dividends in recent years. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. BRIDGEBIO PHARMA operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 385 people. For more info on BridgeBio Pharma please contact Neil Kumar at 650 391 9740 or go to https://bridgebio.com.BridgeBio Pharma Investment Alerts
| The company reported the revenue of 353.78 M. Net Loss for the year was (495.27 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. | |
| BridgeBio Pharma has accumulated about 837.66 M in cash with (470.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59. | |
| Over 95.0% of the company shares are owned by institutions such as pension funds | |
| Latest headline from news.google.com: Assessing BridgeBio Pharma Valuation After Recent Share Price Volatility - Yahoo Finance |
BridgeBio Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 12.79 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BridgeBio Pharma's market, we take the total number of its shares issued and multiply it by BridgeBio Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.BridgeBio Profitablity
BridgeBio Pharma's profitability indicators refer to fundamental financial ratios that showcase BridgeBio Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, BridgeBio Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, BridgeBio Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of BridgeBio Pharma's profitability requires more research than a typical breakdown of BridgeBio Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.13. Management Efficiency
BridgeBio Pharma has return on total asset (ROA) of (0.4348) % which means that it has lost $0.4348 on every $100 spent on assets. This is way below average. BridgeBio Pharma's management efficiency ratios could be used to measure how well BridgeBio Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Leadership effectiveness at BridgeBio Pharma is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 2nd of February, BridgeBio Pharma shows the Mean Deviation of 1.94, risk adjusted performance of 0.151, and Downside Deviation of 2.36. BridgeBio Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BridgeBio Pharma mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation to decide if BridgeBio Pharma is priced correctly, providing market reflects its regular price of 65.52 per share.BridgeBio Pharma Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. BridgeBio Pharma Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe BridgeBio Pharma price patterns.
BridgeBio Pharma Predictive Daily Indicators
BridgeBio Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BridgeBio Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BridgeBio Pharma Forecast Models
BridgeBio Pharma's time-series forecasting models are one of many BridgeBio Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BridgeBio Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in BridgeBio Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
BridgeBio Pharma Corporate Management
Elected by the shareholders, the BridgeBio Pharma's board of directors comprises two types of representatives: BridgeBio Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BridgeBio. The board's role is to monitor BridgeBio Pharma's management team and ensure that shareholders' interests are well served. BridgeBio Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BridgeBio Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CPC | Chief Officer | Profile | |
| Richard Scheller | Chairman of Research and Development, Director | Profile | |
| Maricel Apuli | Chief Officer | Profile | |
| Eli Wallace | Chief Oncology | Profile | |
| Michael Henderson | Chief Business Officer | Profile | |
| Andrew Lo | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. For more detail on how to invest in BridgeBio Stock please use our How to Invest in BridgeBio Pharma guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.